Medication info
OMPS Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

OMPS Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Dihydrate›43.38mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Pink oblong film-coated tablet
Packaging
28 tablets (7 tablets/PTP x 4)
Approval status
Active

MFDS item code 201402912 · Approved 2014.06.30 · Insurance code 643306790

Summary

Main use
Treatment and prevention of acid-related disorders, Helicobacter pylori infection, ulcers and rebleeding, and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to use of nonsteroidal anti-inflammatory drugs. Combination therapy with antibiotics for eradication of Helicobacter pylori: Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors): 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. No clinical trials longer than 4 weeks have been conducted. Treatment of gastric ulcers associated with use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. Maintenance therapy following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers: Administer 40 mg once daily for 4 weeks following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal failure. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly patients: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to use of nonsteroidal anti-inflammatory drugs. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment and prevention of acid-related disorders, Helicobacter pylori infection, ulcers and rebleeding, and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • Helicobacter pylori positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding of gastric ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, particularly erosive esophagitis, and for long-term maintenance therapy to prevent recurrence in patients with esophagitis. It also helps to relieve symptoms of gastroesophageal reflux disease without esophagitis. It is often used in combination with antibiotics for the treatment of peptic ulcers caused by Helicobacter pylori infection. It is effective for alleviating upper gastrointestinal symptoms related to non-steroidal anti-inflammatory drugs, treatment of gastric ulcers, and prevention of ulcers, and is also used in the management of Zollinger-Ellison syndrome. It aids in maintaining after the prevention of rebleeding due to gastric or duodenal ulcers. Thus, it is used for various gastrointestinal disorders and symptom improvement.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to use of nonsteroidal anti-inflammatory drugs. Combination therapy with antibiotics for eradication of Helicobacter pylori: Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors): 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. No clinical trials longer than 4 weeks have been conducted. Treatment of gastric ulcers associated with use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. Maintenance therapy following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers: Administer 40 mg once daily for 4 weeks following intravenous treatment to induce prevention of rebleeding due to gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal failure. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly patients: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to use of nonsteroidal anti-inflammatory drugs. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be used in patients who are hypersensitive to this drug, its components, or benzimidazole derivatives. Additionally, patients allergic to amoxicillin or clarithromycin should not receive this medication when used in combination for Helicobacter pylori eradication therapy. Patients taking specific drugs such as terfenadine, cisapride, pimozide, or astemizole, or patients on atazanavir, nelfinavir, or rilpivirine should also refrain from using this medication. Women who are breastfeeding should avoid taking this drug. This medication may lead to various adverse reactions, so if symptoms such as headache, abdominal pain, diarrhea, skin rash, muscle pain, blood abnormalities, or changes in mental state occur, it is crucial to consult a doctor immediately. Regular check-ups are necessary for long-term use, especially if taken for more than a year, and any changes in symptoms should be discussed with healthcare providers. Since this medication inhibits gastric acid secretion, it may increase bacterial growth in the gastrointestinal tract, so it is important to inform healthcare providers if diarrhea persists or worsens. Patients with osteoporosis or those at high risk of fractures should carefully monitor bone health during prolonged use. This medication is not suitable for patients with specific genetic metabolic abnormalities, so those with fructose intolerance or glucose-galactose malabsorption should not take it. Moreover, potential interactions may occur with other medications taken alongside this one; therefore, it is imperative to inform doctors or pharmacists of any medications being used. Data on the safety of this drug during pregnancy is limited, so it should be administered with caution during pregnancy, in consultation with healthcare providers. There is no specific antidote for overdose, so appropriate treatment should be administered based on symptoms, and it is safest to keep it out of the reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, agitation, confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, oral mucositis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Riel syndrome, acute generalized exanthematous pustulosis, eosinophilia and systemic symptoms associated drug reactions, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsened constipation, dyspepsia, dysphagia, gastrointestinal developmental disorders, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, agitation, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, dizziness, visual field loss, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, hyposmia, taste loss, taste disorder, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, asthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to maintain room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink oblong film-coated tablet

Package unit

28 tablets (7 tablets/PTP x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.